Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease by Ohashi, Naro et al.
© 2012 Ohashi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nephrology and Renovascular Disease 2012:5 53–60
International Journal of Nephrology and Renovascular Disease
Methoxy polyethylene glycol-epoetin beta  






1Internal Medicine 1, 2Blood 
Purification Unit, Hamamatsu 
University School of Medicine, 
Hamamatsu, Shizuoka, Japan
Correspondence: Naro Ohashi 
Internal Medicine 1, Hamamatsu 
University School of Medicine,  
1-20-1 Handayama, Higashi-ku,  
Hamamatsu 431-3192, Japan 
Tel +81 53 435 2261 
Fax +81 53 434 9447 
Email ohashi-n@hama-med.ac.jp
Abstract: Chronic kidney disease (CKD) is a risk factor for end-stage renal failure and 
  cardiovascular events. In patients with CKD, anemia is often caused by decreased erythropoietin 
production relative to hemoglobin levels. As correction of anemia is associated with improved 
cardiac and renal function and quality of life, erythropoiesis-stimulating agents (ESAs) are 
standard therapy for anemia in CKD patients. However, traditional ESAs such as epoetin 
or darbepoetin have short half-lives and require frequent administration, dose changes, and 
close monitoring of hemoglobin concentration to maintain target hemoglobin levels. Methoxy 
polyethylene glycol-epoetin beta (MPG-EPO) is the only ESA that is generated by chemical 
modification of glycosylated erythropoietin through the integration of one specific, long, linear 
chain of polyethylene glycol. This ESA induces continuous erythropoietin receptor activation 
and has a long half-life (approximately 130 hours). Subcutaneous or intravenous administration 
of MPG-EPO once every 2 weeks or monthly achieved a high hemoglobin response rate in 
patients with anemia associated with CKD, regardless of whether the patient was undergoing 
dialysis. According to data from an observational time and motion study, MPG-EPO maintains 
hemoglobin levels when the same dose is administered, however infrequently. This suggests 
that compared with the use of traditional ESAs, administration of MPG-EPO reduces the overall 
time and cost associated with the management of anemia in CKD patients undergoing dialysis. 
MPG-EPO is generally well tolerated and most adverse events are of mild to moderate severity. 
The most commonly reported adverse effects are hypertension, nasopharyngitis, and diarrhea. 
Subcutaneous injection of MPG-EPO is significantly less painful than subcutaneous injection of 
darbepoetin. In conclusion, MPG-EPO is as effective and safe as traditional ESAs in managing 
renal anemia, irrespective of whether the patient is undergoing dialysis.
Keywords: methoxy polyethylene glycol-epoetin beta, renal anemia, end-stage renal failure, 
hemoglobin, erythropoiesis-stimulating agent
Introduction
Chronic kidney disease (CKD) is a known risk factor for end-stage renal failure and 
cardiovascular events.1 Anemia is a common complication in patients with CKD. The 
most probable reason for a decline in hemoglobin levels in CKD patients is decreased 
erythropoietin production relative to hemoglobin levels.2 Correction of anemia is 
associated with improved cardiac and renal function and quality of life.3 Therefore, 
erythropoiesis-stimulating agents (ESAs) are standard therapy for renal anemia in 
CKD patients.
ESAs are glycated proteins with a peptide core of 165 amino acids. A major 
  limitation of epoetin, the first ESA to be marketed, is that it is usually administered by 
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injection two or three times per week.4 To develop a longer-
acting erythropoietic agent, additional N-linked glycosylation 
sites were introduced into erythropoietin by site-directed 
mutagenesis.5 This modification resulted in a 37.1-kDa gly-
coprotein, darbepoetin alfa (DA), the half-life of which is 
three times that of epoetin, thus only needs to be administered 
by injection once weekly, or once every 2 weeks in most 
patients.6,7 However, conventional treatment with ESAs to 
manage anemia in CKD patients requires frequent adminis-
tration, dose changes, and close monitoring of hemoglobin 
concentration to maintain target hemoglobin levels.
Methoxy polyethylene glycol-epoetin beta (MPG-EPO; 
Mircera®, Roche, Basel, Switzerland) is a novel agent that 
has a different interaction with the erythropoietin receptor 
than previous agents and has a long elimination half-life 
(approximately 130 hours).8 MPG-EPO is the only ESA 
generated by chemical modification of glycosylated erythro-
poietin, by the integration of one specific, long, linear chain 
of polyethylene glycol. The resultant molecule has a molecu-
lar weight of approximately 60 kDa, which is twice that of 
epoetin. The methoxy polyethylene glycol polymer chain 
is integrated through amide bonds between the N-terminal 
amino group or the ε-amino group (predominantly lysine-52 
or lysine-45) with a single butanoic acid linker.9
The interaction between MPG-EPO and the   erythropoietin 
receptor differs from that of epoetin beta.10 The comparative 
erythropoietin receptor-binding properties of MPG-EPO and 
epoetin beta were assessed by surface plasmon resonance 
using soluble recombinant EPO receptors and by competi-
tion binding on cultured UT-7 cells. Calculated equilibrium 
dissociation constants (surface plasmon resonance assay) 
for MPG-EPO and epoetin beta were 140 and 2.9 nmol/L, 
respectively. Respective IC50 values (competition binding 
assay) were 200 and 1.5 nmol/L. Compared with epoetin 
beta, MPG-EPO has an approximately 50- to 100-fold lower 
affinity for erythropoietin receptor-binding sites. Analysis of 
the equilibrium binding curves indicates that the   difference 
in affinity is mainly due to slower association. The   different 
receptor-binding properties of MPG-EPO may enable 
continuous stimulation of erythropoiesis combined with a 
long half-life and slow systemic clearance.10 As a result, 
MPG-EPO stimulates erythropoiesis when administered 
intravenously or subcutaneously at a prolonged dosing 
interval (Table 1).
This review focuses on the therapeutic efficacy and toler-
ability of MPG-EPO in CKD patients with renal anemia who 
are or are not undergoing dialysis.
Therapeutic efficacy
Several Phase I, four Phase II, and seven Phase III random-
ized open-label, parallel-group, multicenter studies have 
investigated the therapeutic efficacy of MPG-EPO in CKD 
patients with renal anemia (Table 2).8,11–22 These studies 
have included patients who were or were not undergo-
ing dialysis. In addition, the open-label, non-comparative 
(MIRACEL) study assessed the efficacy of MPG-EPO in a 
real-life situation.23
In a Phase I trial using healthy volunteers (n = 42), 
  subcutaneous administration of MPG-EPO in the arm, thigh, 
or abdomen (3.0 µg/kg) increased mean reticulocyte counts 
relative to baseline by 258%, 273%, and 269%, respectively. 
These results suggest that the pharmacokinetic and phar-
macodynamic properties of MPG-EPO effectively increase 
reticulocyte counts, irrespective of the skin site of subcutane-
ous administration.11 Similarly, in a Phase I trial in patients 
receiving peritoneal dialysis (n = 16), a single subcutaneous 
(0.8 µg/kg) or intravenous (0.4 µg/kg) dose of MPG-EPO 
induced a reticulocyte response that peaked at a median of 
8 days after administration and returned to baseline values 
by day 20. The time course for reticulocyte counts was not 
different between the two routes of administration. These 
results suggest that extended administration intervals of 
MPG-EPO are feasible in patients with CKD.8
In the Phase II trials, four studies determined the admin-
istration intervals and optimal starting dose in patients with 
CKD, some of whom were undergoing dialysis, while others 
Table 1 Half-lives of erythropoiesis-stimulating agents (ESAs)
ESA Population Mean half-life (h)
Intravenous administration Subcutaneous administration
Epoetin alfa Healthy volunteers4 6.8 19.4
Epoetin beta Healthy volunteers4 8.8 24.2
Darbepoetin alfa CKD patients not on dialysis6 69.6
CKD patients on dialysis7 25.3 48.8
Methoxy polyethylene glycol-epoetin beta CKD patients on dialysis8 134 139
Abbreviation: CKD, chronic kidney disease.
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were not.12–15 de Francisco et al investigated 61 ESA-naïve 
patients with CKD who were undergoing dialysis and were 
randomized to MPG-EPO treatment at doses of 0.15, 0.30, 
and 0.45 µg/kg once per week.12 Within these dose groups, 
patients were further randomized into once weekly, once 
every 2 weeks, or once every 3 weeks groups. In total, 90% 
of patients in the 0.30 µg/kg once per week group and 79% of 
patients in the 0.45 µg/kg once per week group responded to 
treatment (hemoglobin increase, $1.0 g/dL), compared with 
72% in the 0.15 µg/kg once per week group and the response 
was unrelated to administration frequency. Provenzano et al 
studied administration intervals (once every 1, 2, or 4 weeks) 
and optimal starting doses (0.15, 0.30, or 0.60 µg/kg once per 
week) of MPG-EPO subcutaneously administered in ESA-
naïve patients with CKD who were not receiving dialysis.15 
The hemoglobin response rate increased with escalating doses, 
with 67%, 72%, and 90% of patients responding in the groups 
treated with MPG-EPO at 0.15, 0.30, and 0.60 µg/kg once per 
week, respectively, and the response was unrelated to admin-
istration frequency. Overall, these results suggest that 0.60 µg/
kg of MPG-EPO administered subcutaneously or intravenously 
once every 2 weeks is an optimal starting dose and a suitable 
time interval for the initiation of anemia correction in patients 
with CKD, regardless of dialysis dependency.
Two Phase III studies investigated the efficacy of intra-
venous or subcutaneous MPG-EPO administered once every 
Table 2 Therapeutic efficiency of methoxy polyethylene glycol-epoetin beta
Method, dose, and frequency  
of administration
Population Numbers Results
A single SC dose (0.8 µg/kg) or Iv dose  
(0.4 µg/kg)8
Patients on PD 16 MPG-EPO has a prolonged half-life after 
Iv (134 h) and SC (139 h) administration
A single SC dose (3.0 µg/kg)11 Healthy volunteers 42 MPG-EPO increases reticulocyte counts, 
irrespective of the skin site of SC 
administration
SC doses (0.15, 0.30, and 0.45 µg/kg) 
once every 1, 2, or 3 weeks12
ESA-naïve patients on dialysis 61 SC dose (0.60 µg/kg) once every 2 weeks 
is optimal in CKD patients on dialysis
Iv doses (0.25, 0.4, or 0.6 µg/kg/week)13 Patients on dialysis converted  
from EPO
91 Administration can be switched from 
EPO 3 times/week to MPG-EPO once 
every 1 or 2 weeks
SC doses (0.4, 0.8, or 1.2 µg/kg)  
once every 1, 3, or 4 weeks14
Patients on dialysis converted  
from SC EPO
137 SC MPG-EPO at up to once-monthly 
intervals provides stable Hgb levels in 
dialysis patients converting from EPO  
1–3 times/week
SC doses (0.15, 0.3, or 0.6 µg/kg)  
once every 1, 2, or 4 weeks15
ESA-naïve patients not  
on dialysis
91 SC (0.6 µg/kg) dose once every 
2 weeks is optimal in CKD patients 
not on dialysis
Iv dose (0.4 µg/kg) once every  
2 weeks16 (AMICUS study)
Patients on dialysis 181 Iv MPG-EPO once every 2 weeks is safe 
and effective as 3 times weekly EPO  
for correcting anemia
SC dose (0.6 µg/kg) once every  
2 weeks17 (ARCTOS study)
ESA-naïve patients not  
on dialysis
324 SC MPG-EPO once every 2 weeks is as 
safe as DA once every 1 week
Iv doses (60, 100, 180 µg) once every  
2 weeks and Iv doses (120, 200, 360 µg)  
once every 4 weeks18 (MAXIMA study)
Patients on HD converted  
from Iv EPO
673 Iv MPG-EPO is as safe as conventional 
EPO treatment and can maintain anemia 
management from Iv EPO
SC doses (60, 100, 180 µg) once every  
2 weeks and SC doses (120, 200, 360 µg)  
once every 4 weeks19 (PROTOS study)
Patients on HD converted  
from SC EPO
572 SC MPG-EPO once every 2 or 4 weeks 
maintains tight and stable Hgb levels from 
SC EPO
Iv doses (60, 100, 180 µg) once every  
2 weeks20 (STRIATA study)
Patients on HD converted  
from Iv DA
313 Stable Hgb levels are maintained in 
patients on HD converted Iv MPG-EPO 
every 2 weeks from DA
SC/Iv doses (60, 100, 180 µg) once every  
2 weeks21 (RUBRA study)
Patients on dialysis converted  
from SC/Iv EPO
336 MPG-EPO once every 2 weeks maintains 
stable Hgb control in patients on dialysis 
converted from EPO
Iv doses (120, 200, or 360 µg) once every  
4 weeks22 (PATRONUS)
Patients on HD converted  
from Iv DA
490 MPG-EPO maintains target Hgb more 
successfully than DA
Abbreviations: SC, subcutaneous; Iv, intravenous; PD, peritoneal dialysis; MPG-EPO, methoxy polyethylene glycol-epoetin beta; ESA, erythropoiesis-stimulating agent; 
CKD, chronic kidney disease; EPO, epoetin; Hgb, hemoglobin; DA, darbepoetin alfa; HD, hemodialysis.
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2 weeks in ESA-naïve patients with renal anemia who were 
either receiving dialysis (CERA [continuous erythropoietin 
receptor activator (methoxy polyethylene glycol-epoetin 
beta)] adMinistered Intravenously for anemia Correction 
and sUStained maintenance in dialysis [AMICUS]) or not 
(Administration of CERA in CKD patients to treat anemia 
with a Twice-monthly Schedule [ARCTOS]).16,17 In the 
AMICUS study, patients with CKD stage 5D who were 
receiving hemodialysis or peritoneal dialysis (n = 181) 
were recruited. After a 2-week run in, patients were ran-
domly assigned to receive MPG-EPO or epoetin (epoetin 
alfa or beta). The MPG-EPO dose was started at 0.4 µg/kg, 
which was adjusted to achieve a defined hemoglobin 
response ($11 g/dL), and an increase of $1.0 g/dL from 
the patients’ baseline hemoglobin levels during a 24-week 
correction period. Hemoglobin response rates (intent-to-
treat   population) were 93.3% with MPG-EPO and 91.3% 
with epoetin. The mean changes in hemoglobin levels 
from baseline to the end of the correction period were 
2.70 ± 1.45 g/dL with MPG-EPO and 2.56 ± 1.31 g/dL 
with epoetin. These results show the utility of intravenous 
MPG-EPO administered once every 2 weeks in ESA-naïve 
dialysis patients.16
In the ARCTOS study, patients who had CKD and were 
not receiving dialysis (n = 324) were recruited. Patients were 
randomly assigned to receive MPG-EPO once every 2 weeks 
or DA once weekly during an 18-week correction period 
and a 10-week evaluation period. The MPG-EPO dose was 
started at 0.6 µg/kg and was adjusted to achieve a defined 
hemoglobin response ($11 g/dL) and an increase of $1.0 g/
dL from the patients’ baseline hemoglobin levels during a 
28-week period after the first dose. Hemoglobin response 
rates were 97.5% for MPG-EPO and 96.3% for DA. The mean 
changes in hemoglobin levels from baseline to evaluation 
were 2.15 g/dL for MPG-EPO and 2.00 g/dL for DA. These 
results show that subcutaneous administration of MPG-EPO 
once every 2 weeks corrects anemia in ESA-naïve patients 
who are not receiving dialysis.17
Five Phase III maintenance studies (Maintenance of 
hAemoglobin eXcels with IV adMinistration of CERA 
[MAXIMA],18 Patients Receiving CERA Once a month 
for the mainTenance Of Stable hemoglobin [PROTOS],19 
Stabilizing haemoglobin TaRgets in dialysis following 
IV CERA Treatment of Anaemia [STRIATA],  TaRgeting 
sUstained hemogloBin in dialysis with IV and SC CERA 
Administration [RUBRA], and comPArator sTudy of 
CERA and darbepOetin alfa in patieNts Undergoing 
dialySis [PATRONUS]) investigated the efficacy of 
  intravenous or subcutaneous MPG-EPO in maintaining 
stable hemoglobin levels in CKD patients with renal ane-
mia on dialysis who had been converted from another ESA 
(epoetin alfa or beta or DA).18–22
In the MAXIMA, PROTOS, STRIATA, and RUBRA 
studies, patients were randomized to groups in which 
MPG-EPO was administered once every 2 or 4 weeks, or 
in which their current ESA (epoetin alfa or beta, or DA) 
dose was continued.18–22 Patients in these trials had been 
receiving hemodialysis or peritoneal dialysis and had stable 
baseline hemoglobin levels of 10.5–13.0 g/dL with adequate 
iron status. The doses were adjusted during a 28-week titra-
tion period followed by an 8-week evaluation period to 
maintain the hemoglobin levels within 10–13.5 g/dL and 
within ±1 g/dL of the baseline hemoglobin value. During 
the evaluation period, 66%–76% of MPG-EPO recipients, 
67%–72% of epoetin alfa or beta recipients, and 72% of 
DA recipients maintained an average hemoglobin level 
within ±1 g/dL of baseline values.18–21 During the titration 
and evaluation periods, blood transfusions were required by 
6%–12% of patients treated with MPG-EPO and 8%–10% of 
patients treated with traditional ESAs.18–21 The results of these 
Phase III maintenance studies demonstrate that MPG-EPO 
administered once every 2 or 4 weeks is comparable to 
epoetin alfa, epoetin beta (MAXIMA, PROTOS, RUBRA), 
or DA (STRIATA) in maintaining stable hemoglobin levels 
over the evaluation period.
Erythropoietin resistance is one of the main causes for 
anemia in patients with CKD. Up to 10% of patients receiv-
ing erythropoietin are hyporesponsive to the therapy and 
require large doses of the agent.24 All of the ESA (MPG-
EPO, epoetin alfa or beta, and DA) recipients maintained 
stable hemoglobin levels and there were no differences in 
percentages of blood transfusions in the above studies.18–21 
These data suggest that frequency of erythropoietin resistance 
is similar among MPG-EPO, epoetin alfa or beta, and DA. 
It has been reported that the hemoglobin cycling described 
by Fishbane and Berns is associated with adverse outcomes 
such as increases in morbidity and mortality.25 Selby et al 
described a trend toward fewer patients on MPG-EPO 
(68.4%) experiencing hemoglobin excursions than on epoetin 
beta (87.8%, P = 0.054), and that the MPG-EPO group also 
required fewer dose changes.26 These data demonstrate that 
the longer half-life of MPG-EPO may offer a small advantage 
in reducing the degree of hemoglobin variability, possibly 
because of fewer dose changes per patient.
The PATRONUS study was a multinational, randomized, 
prospective trial that compared hemoglobin maintenance 
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achieved with once per month administration of MPG-EPO 
and DA. After the 26-week titration period using MPG-EPO 
once monthly or DA every 2 weeks, patients entered a second 
26-week period of once per month MPG-EPO and DA. Doses 
of MPG-EPO increased by 6.8% and those of DA increased 
by 58.8% during once-monthly treatment, indicating that 
MPG-EPO maintained target hemoglobin more efficiently 
than DA at once per month dosing intervals.22
The MIRACEL study was a prospective, open-label, 
multicenter study performed at 90 nephrology centers 
in   Germany, which was undertaken to examine whether 
monthly administration of MPG-EPO maintains stable hemo-
globin levels when administered according to local clinical 
judgment.23 Of the 661 screened hemodialysis patients, 424 
receiving epoetin or DA were converted to monthly intra-
venous MPG-EPO, with a 5-month titration phase followed 
by a 2-month evaluation phase. A mean of two MPG-EPO 
dose changes were required during the 7-month treatment 
period. During the screening, titration, and evaluation phases, 
mean hemoglobin was 11.7 ± 0.7 g/dL, 11.6 ± 0.9 g/dL, and 
11.4 ± 1.0 g/dL, respectively. Patients exhibiting a change 
of #1 g/dL from phase-specific individual means was 90.6%, 
70.4%, and 82.9%, respectively. These results indicate that 
the conversion of hemodialysis patients from epoetin or DA 
to monthly MPG-EPO is practical, convenient, and provides 
adequate control of hemoglobin levels.
Tolerability
In the MAXIMA study,18 of 673 randomized patients, 666 
receiving MPG-EPO every 2 weeks (n = 221), MPG-EPO 
every 4 weeks (n = 220), or epoetin 1–3 times per week 
(n = 225) received at least one treatment. At least one adverse 
event was reported in 619 (93%) of patients (MPG-EPO 
every 2 weeks [n = 203], MPG-EPO every 4 weeks [n = 202], 
or epoetin 1–3 times per week [n = 214]); most adverse events 
were mild to moderate. The incidence of adverse events did 
not differ between groups (P = 0.12).
The most commonly reported adverse effects were 
  hypertension, nasopharyngitis, headache, and diar-
rhea. In addition, 287 patients had serious adverse events 
in the three groups (MPG-EPO every 2 weeks [n = 101], 
MPG-EPO every 4 weeks [n = 87], or epoetin 1–3 times per 
week [n = 99]). The most common serious adverse events 
were sepsis, pneumonia, and arteriovenous graft thrombo-
sis. Only six patients had serious adverse events that were 
judged to be treatment related and the occurrence of serious 
adverse events did not differ between groups (MPG-EPO 
every 2 weeks [n = 3], MPG-EPO every 4 weeks [n = 2], or 
epoetin 1–3 times per week [n = 1]; P = 0.40) (Table 3A). 
The results of the PROTOS study were similar to those of 
the MAXIMA study. In total, 90% of patients across all 
treatment groups (twice per month MPG-EPO [90.0%], once 
per month MPG-EPO [93.2%], or epoetin 1–3 times weekly 
[87.4%]) experienced at least one adverse event.
The most commonly reported adverse effects were 
hypertension, procedural hypotension (hypotension dur-
ing dialysis), nasopharyngitis, headache, and diarrhea. 
Most events were mild or moderate in intensity and were 
evenly distributed across the different treatment groups. 
The incidence of treatment-related adverse events was low 
(twice-monthly MPG-EPO, 4%; once-monthly MPG-EPO, 
6%; and epoetin 1–3 times weekly, 2%). Only one death was 
considered to be related to study treatment (once-monthly 
MPG-EPO; gastrointestinal necrosis followed by sepsis) 
(Table 3B).19 In addition, the occurrences of cerebral hemor-
rhage (0.2%), myocardial infarction (0.2%), and hypertensive 
encephalopathy (0.2%) were limited, according to the patient 
package insert from the pharmaceutical company.27 These 
results indicate that MPG-EPO is as well tolerated and safe 
as conventional ESA treatments. However, the long-term 
adverse effects of MPG-EPO need to be ascertained.
Pain following subcutaneous administration of MPG-EPO 
or DA was compared among healthy volunteers (n = 84). Pain 
was assessed on a 100 mm visual analog scale immediately 
after drug administration. Visual analog scale was 21.5 mm 
for MPG-EPO and 33.4 mm for DA (P , 0.0001), showing 
that subcutaneous injection of MPG-EPO is significantly less 
painful than subcutaneous injection of DA.28
Pharmacoeconomics
An observational time and motion study was carried out in 
twelve dialysis centers in the UK and Germany (six centers 
per country).29 Time measurements for observed tasks were 
obtained by trained observers using a stopwatch. Cost results 
in 2006 were expressed as average observed costs, including 
staff costs for observation periods and costs of supplies. ESA 
drug acquisition costs were not considered in the analysis. 
According to this study, the estimated average total annual 
costs for traditional ESA treatment for a hypothetical center 
of 100 dialysis patients were €17,031 and GBP₤18,739 for 
German and UK centers, respectively. Assuming 100% con-
version from traditional ESAs to once-monthly MPG-EPO in 
a hypothetical center of 100 dialysis patients, the estimated 
time savings were 36.9 days per year in an average UK center, 
and 43.4 days per year in an average German center. This 
leads to an estimated reduction in annual costs of €9,798 
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(-58%) for the German center and GBP₤6,615 (-35%) for 
the UK center. These data suggest that once-monthly MPG-
EPO reduces the overall time and cost associated with anemia 
management in CKD patients on dialysis compared with the 
use of traditional ESAs.
Dosage and administration
In ESA-naïve patients, the recommended starting dose is 
0.6 µg/kg administered once every 2 weeks as a subcutaneous 
or intravenous injection, in order to reach a hemoglobin level 
of .11 g/dL. The dose may be increased by approximately 
25% if hemoglobin levels increase by ,1.0 g/dL over a month. 
Further increases of approximately 25% may be made once per 
month until the individual target hemoglobin level is reached. 
If a hemoglobin level of .11 g/dL is reached for an individual 
patient, MPG-EPO may be continued once per month using a 
dose equal to twice the previous dose once every 2 weeks.
Patients currently being treated with ESA can be directly 
converted to MPG-EPO administered once per month as 
a single intravenous or subcutaneous injection. The start-
ing dose of this agent is based on the calculated weekly 
equivalent dose of DA or epoetin at the time of conversion 
(Table 4). The first injection of MPG-EPO should start at 
the next scheduled dose of the previously administered DA 
or epoetin dose.
In patients receiving treatment with ESA and in those 
naïve to ESA, the MPG-EPO dose should be reduced by 
approximately 25% if the hemoglobin level increases by 
more than 2 g/dL in 1 month or if the hemoglobin level 
approaches 12 g/dL. If hemoglobin levels continue to 
increase, MPG-EPO administration should be interrupted 
until these levels begin to decrease (a decrease of approxi-
mately 0.35 g/dL per week is expected). Therapy should 
then be resumed at a dose approximately 25% less than the 
Table 3 Adverse events of methoxy polyethylene glycol-epoetin beta
Adverse events Methoxy polyethylene  
glycol-epoetin beta every 2 weeks  
(n = 221)
Methoxy polyethylene  
glycol-epoetin beta every  
4 weeks (n = 220)
Epoetin 1–3 times  
per week  
(n = 225)
(A) Adverse events in the MAXIMA study18
Any adverse event 203 (92%) 202 (92%) 214 (95%)
  Diarrhea 38 (17%) 26 (12%) 30 (13%)
  Nasopharyngitis 28 (13%) 39 (18%) 24 (11%)
  Hypertension 23 (10%) 29 (13%) 35 (16%)
  Arteriovenous graft thrombosis 25 (11%) 26 (12%) 32 (14%)
  Upper respiratory tract infection 20 (9%) 30 (14%) 25 (11%)
  Headache 30 (14%) 17 (8%) 24 (11%)
  Fluid overload 27 (12%) 22 (10%) 17 (8%)
  Muscle spasms 19 (9%) 19 (9%) 24 (11%)
Serious adverse events 101 (46%) 87 (40%) 99 (44%)
  Sepsis 5 (2%) 6 (3%) 9 (4%)
  Pneumonia 9 (4%) 5 (2%) 5 (2%)
  Arteriovenous graft thrombosis 2 (1%) 8 (4%) 7 (8%)
Twice-monthly CERA  
(n = 190)
Once-monthly CERA  
(n = 191)
Epoetin 1–3 times  
per week (n = 191)
(B) Adverse events in the PROTOS study19
Hypertension 27 (14%) 30 (16%) 25 (13%)
Procedural hypotension 17 (9%) 29 (15%) 20 (10%)
Nasopharyngitis 18 (9%) 19 (10%) 18 (9%)
Headache 15 (8%) 20 (11%) 19 (10%)
Diarrhea 20 (11%) 15 (8%) 14 (7%)
Muscle spasms 16 (8%) 14 (7%) 17 (9%)
Fluid overload 9 (5%) 15 (8%) 18 (9%)
Arteriovenous fistula site hemorrhage 18 (9%) 15 (8%) 5 (3%)
Arteriovenous fistula thrombosis 13 (7%) 15 (8%) 8 (4%)
Angina pectoris 2 (1%) 15 (8%) 4 (2%)
Any adverse events 170 (90.0%) 177 (93.2%) 167 (87.4%)
Serious adverse events 70 (36.8%) 73 (38.4%) 85 (44.5%)
Abbreviation: CERA, continuous erythropoietin receptor activator (methoxy polyethylene glycol-epoetin beta).
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previously administered dose. Dose adjustments should not 
be made more frequently than once per month.
Since treatment experience is limited in patients receiving 
peritoneal dialysis, regular hemoglobin monitoring and strict 
adherence to dose adjustment guidance is recommended in 
this population.30,31
Conclusion
Among patients with anemia associated with CKD, regard-
less of whether the patient is receiving dialysis, subcutane-
ous or intravenous administration of MPG-EPO achieves a 
high hemoglobin response rate in ESA-naïve patients when 
administered once every 2 weeks and maintains stable hemo-
globin levels in patients previously treated with ESAs when 
administered once per month. MPG-EPO is as well tolerated 
and safe as traditional ESA treatments. In addition, compared 
with the use of traditional ESAs, administration of MPG-EPO 
may reduce the overall time and cost associated with anemia 
management in CKD patients.
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